Critical Path Institute’s New Business Model: An Interview With CEO Compton

After six months on the job, Carolyn Compton, the institute’s new chief executive, has overhauled the funding rules to allow fees from big pharma to cover overhead as government funding dries up. Successor to founder Raymond Woosley, who retired last year, Compton shares her vision for securing the institute’s finances for the future amid tough economic times.

In a tough economic climate, the time has come for a new business model at the Critical Path Institute, a nonprofit public-private partnership, says Carolyn Compton, who assumed the position of CEO in February, taking over from founder Raymond Woosley.

Born in 2005, the extra-governmental organization, often called C-Path, has emerged as a showcase for FDA’s Critical Path Initiative, aimed at improving efficiency of drug development Also see "A Critical Test for FDA's Critical Path Initiative" - Pink Sheet, 1 February, 2006.

More from United States

More from North America